Welcome to our dedicated page for Niagen Bioscience SEC filings (Ticker: NAGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Niagen Bioscience, Inc. (NASDAQ: NAGE) SEC filings page on Stock Titan aggregates the company’s official disclosures to the U.S. Securities and Exchange Commission, offering a structured view into how this NAD+ and healthy-aging focused bioscience business reports its operations, strategy, and governance. These documents complement the company’s press releases by providing formal detail on financial results, material agreements, equity plans, and other regulatory matters.
For investors tracking NAGE, periodic reports such as Forms 10-K and 10-Q (when available) are central references for understanding revenue drivers like Tru Niagen® consumer supplements, Niagen® ingredient sales, and pharmaceutical-grade Niagen Plus™ IV and injectable products. They also typically describe research and development priorities, intellectual property portfolios around nicotinamide riboside and other NAD+ precursors, and risk factors relevant to the company’s position in the biotechnology and dietary supplement markets.
Current reports on Form 8-K, several of which are summarized in the recent record, document specific events such as quarterly earnings announcements, share repurchase program authorizations, changes to financial outlook, material supply agreements for nicotinamide-beta-riboside chloride, and patent assignment transactions with Queen’s University Belfast. Other filings detail stockholder approvals of equity incentive plan amendments and employee stock purchase plans, which shape dilution and compensation structures.
On Stock Titan, these filings are paired with AI-powered summaries that help explain complex sections, from revenue and margin discussions to the implications of IP and supply agreements. Users can quickly scan key points in 10-K and 10-Q reports, review 8-K event disclosures, and access information relevant to insider and equity activity through forms such as Form 4 when available. Real-time updates from EDGAR ensure that new Niagen Bioscience filings appear promptly, while AI-generated highlights make it easier to interpret how each document fits into the company’s broader NAD+ science and healthy-aging strategy.
Niagen Bioscience, Inc. reported second‑quarter 2026 results with net sales of $29.8 million versus $31.1 million a year earlier. Gross margin was 64.8%. The company generated net income of $1.0 million, diluted EPS of $0.01, and Adjusted EBITDA of $3.0 million. For the first six months of 2026 it produced $1.6 million of operating cash flow and ended June 30, 2026 with $66.7 million in cash and cash equivalents, having repurchased $2.8 million of common stock in the quarter.
Tru Niagen® remained the core driver with $24.2 million of Q2 2026 net sales, while direct‑to‑consumer website revenue grew 23% year over year. The company launched the Niagen Plus telehealth platform and at‑home injection kit, obtained LegitScript certification, and added Olympia Pharmaceuticals as a 503B compounding partner. Niagen introduced NB4168, an oral small‑molecule candidate for Ataxia‑Telangiectasia that received FDA Rare Pediatric Disease and EMA Orphan Medicinal Product designations, engaged Evotec for preclinical and IND‑enabling work, rebranded its external research program, and appointed Abhijit Kale, Ph.D., to lead global external research. Management expects 2026 e‑commerce growth of 10–15% and characterizes 2026 as a year of strategic investment with higher operating expenses but continued focus on positive operating cash flow.
BlackRock, Inc. reported beneficial ownership of common stock of Niagen Bioscience, Inc. on a Schedule 13G. BlackRock reported beneficial ownership of 4,161,626 shares of common stock, representing 5.2% of the class. It reported 4,097,677 shares with sole voting power and 4,161,626 shares with sole dispositive power, with no shared voting or dispositive authority.
The filing states that various underlying persons have rights to dividends or sale proceeds in these shares, but no single underlying person has more than five percent of Niagen Bioscience’s outstanding common shares. The report is signed by a BlackRock Managing Director.
Niagen Bioscience, Inc. established an at-the-market equity program allowing sales of up to $50,000,000 of common stock through Canaccord Genuity and Roth Capital as sales agents. The shares may be sold from time to time on Nasdaq Capital Market, where the stock last traded at $3.37 per share on July 8, 2026.
The company will pay the sales agents a 3% commission on gross proceeds and expects to use any net proceeds for working capital and general corporate purposes, including capital expenditures and general and administrative expenses. As of March 31, 2026, net tangible book value was $76.8 million, or $0.97 per share; assuming full use of the ATM at $3.37, net tangible book value would rise to $125.1 million, or $1.32 per share, implying dilution of $2.05 per share to new investors. The ATM is issued under a broader shelf registration permitting up to $125,000,000 of various securities over time.
Niagen Bioscience SVP and General Counsel Carlos Luis Lopez acquired additional company stock through an employee plan. On this Form 4, he received 2,314 shares of common stock at a price of $2.71 per share under Niagen Bioscience’s Employee Stock Purchase Plan, in a transaction exempt under Rules 16b-3(c) and 16b-3(d). After this acquisition, his direct holdings increased to 4,565 common shares.
Niagen Bioscience Chief Financial Officer Pamir Ozan acquired additional company stock as part of compensation. Ozan received 4,255 shares of common stock at $2.71 per share through the Employee Stock Purchase Plan, increasing direct holdings to about 11,627 shares. The filing also shows indirect ownership of about 2,220 shares held by the CFO's spouse.
Niagen Bioscience, Inc. director and Chief Executive Officer Robert N. Fried acquired additional common shares through the company’s Employee Stock Purchase Plan. On June 30, 2026, he received 1,106 shares at $2.71 per share in a transaction classified as a grant or award acquisition exempt under Rule 16b-3(c) and 16b-3(d).
Following this acquisition, Fried directly holds 1,060,087 shares of Niagen Bioscience common stock. The filing also lists various indirect holdings held by trusts and family members, including shares held in irrevocable trusts for Benjamin and Jeremy Fried and in the Fried-Travis Revocable Trust, with the reporting person disclaiming beneficial ownership of these securities.
Niagen Bioscience, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders elected all eight director nominees, including Frank L. Jaksch, Jr., Robert Fried, Steven Rubin, Wendy Yu, Gary Ng, Kristin Patrick, Ann Cohen, and Hamed Shahbazi.
Stockholders also ratified the appointment of Crowe LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 56,152,066 votes for and 2,256,090 against. In addition, they approved, on an advisory basis, the compensation of the company’s named executive officers.
Niagen Bioscience, Inc. filed a shelf registration to offer up to $125,000,000 of common stock, debt securities, warrants and units from time to time under a base prospectus dated June 26, 2026. The filing also includes a sales agreement prospectus supplement for up to $50,000,000 of common stock that may be sold under a Sales Agreement dated June 26, 2026.
The company’s common stock trades on The Nasdaq Capital Market under the symbol NAGE and had a reported last sale price of $3.45 per share on June 24, 2026. As of March 31, 2026, there were 79,624,227 shares outstanding and the company is authorized to issue 150,000,000 shares of common stock. Net proceeds will be used at management’s discretion for general corporate purposes as described in the prospectus.